Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cell implantation therapies for Parkinson's disease using neural stem, transgenic or xenogeneic donor cells
Autore:
Isacson, O; Costantini, L; Schumacher, JM; Cicchetti, F; Chung, S; Kim, SK;
Indirizzi:
Harvard Univ, McLean Hosp, Sch Med, Neuroregenerat Lab, Belmont, MA 02478 USA Harvard Univ Belmont MA USA 02478 uroregenerat Lab, Belmont, MA 02478 USA Harvard Univ, McLean Hosp, Sch Med, Mol Neurobiol Lab, Belmont, MA 02478 USA Harvard Univ Belmont MA USA 02478 ol Neurobiol Lab, Belmont, MA 02478 USA Neuroregenerat Lab, Sarasota, FL 34230 USA Neuroregenerat Lab Sarasota FLUSA 34230 erat Lab, Sarasota, FL 34230 USA Sarasota Mem Hosp, Sarasota, FL 34230 USA Sarasota Mem Hosp Sarasota FL USA 34230 Mem Hosp, Sarasota, FL 34230 USA McLean Hosp, NIH, Udall Parkinsons Dis Res Ctr Excellence, Belmont, MA 02478 USA McLean Hosp Belmont MA USA 02478 es Ctr Excellence, Belmont, MA 02478 USA
Titolo Testata:
PARKINSONISM & RELATED DISORDERS
fascicolo: 3, volume: 7, anno: 2001,
pagine: 205 - 212
SICI:
1353-8020(200107)7:3<205:CITFPD>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
SUBSTANTIA NIGRA TRANSPLANTS; VENTRAL MESENCEPHALIC GRAFTS; EMBRYONIC DOPAMINE NEURONS; FIBROBLAST GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT STRIATUM; LONG-TERM SURVIVAL; INTRASTRIATAL TRANSPLANTS; DENERVATED STRIATUM; FUNCTIONAL RECOVERY;
Keywords:
dopamine; fetal cell; Parkinson's disease; regeneration; stem cells; transplantation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
71
Recensione:
Indirizzi per estratti:
Indirizzo: Isacson, O Harvard Univ, McLean Hosp, Sch Med, Neuroregenerat Lab, Belmont, MA 02478 USA Harvard Univ Belmont MA USA 02478 t Lab, Belmont, MA 02478 USA
Citazione:
O. Isacson et al., "Cell implantation therapies for Parkinson's disease using neural stem, transgenic or xenogeneic donor cells", PARKINS R D, 7(3), 2001, pp. 205-212

Abstract

A new therapeutic neurological and neurosurgical methodology involves cellimplantation into the living brain in order to replace intrinsic neuronal systems, that do not spontaneously regenerate after injury, such as the dopaminergic (DA) system affected in Parkinson's disease (PD) and aging. Current clinical data indicate proof of principle for this cell implantation therapy for PD. Furthermore, the disease process does not appear to negativelyaffect the transplanted cells, although the patient's endogenous DA systemdegeneration continues. However, the optimal cells for replacement, such as highly specialized human fetal dopaminergic cells capable of repairing anentire degenerated nigrostriatal system, cannot be reliably obtained or generated in sufficient numbers for a standardized medically effective intervention. Xenogeneic and transgenic cell sources of analogous DA cells have shown great utility in animal models and some promise in early pilot studiesin PD patients. The cell implantation treatment discipline, using cell fate committed fetal allo- or xenogeneic dopamine neurons and glia, is currently complemented by research on potential stem cell derived DA neurons. Understanding the cell biological principles and developing methodology necessary to generate functional DA progenitors is currently our focus for obtaining DA cells in sufficient quantities for the unmet cell transplantation need for patients with PD and related disorders. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 09:18:58